Biophan CEO Addresses NanoBio Convergence Conference in Special Discussion of Nanotech Biomedical Solutions; CEO Michael Weiner and Guidant Corp. Research Manager Present at Cutting-Edge Technology Seminar
In the presentation, CEO Michael Weiner highlighted Biophan's nanotechnology-based innovations to address a range of multi-billion-dollar segments of the biomedical marketplace. Among other topics, Mr. Weiner discussed the Company's proprietary technology solutions for active drug delivery, designed to enable new applications in a projected $40 billion market. Also presenting at session was Florian Ludwig, Manager of Research & Technology for Guidant Corp., (NYSE: GDT) a leading biomedical manufacturer.
“Through our proprietary and patented technologies, Biophan has already demonstrated that nanotechnology is an answer to many long-running needed health care issues, such as the need for artifact-free and accurate MRI imaging of vascular stents and other medical devices.”
Other Biophan nanotech solutions addressed by Mr. Weiner include such state-of-the-art nanotech product initiatives as the Company's biothermal battery technology designed to generate electricity to power implanted medical devices, and proprietary solutions to make medical devices including vascular stents and vena cava filters fully visible and image-compatible with Magnetic Resonance Imaging (MRI) systems. He also discussed the MYO-VAD(TM), a novel heart pump assist device Biophan is developing with MYOTECH, and its unique potential for drug-delivery and/or cell lines directly to the myocardium. Biophan is
"Biophan has long been a leader in the research and development of nanotechnology-based solutions to tap the huge market potential represented by the convergence of nanotechnology and biotechnology," Mr. Weiner said. "Through our proprietary and patented technologies, Biophan has already demonstrated that nanotechnology is an answer to many long-running needed health care issues, such as the need for artifact-free and accurate MRI imaging of vascular stents and other medical devices.
Biophan is a biomedical development leader with an extensive intellectual property portfolio of 156 U.S. patents, licenses, or applications and 46 international applications.
The Company is focused on commercializing its technology via licensing agreements with large manufacturers. Many of the Company's diverse range of advanced solutions enable implanted medical devices and other medical tools to be used safely and imaged effectively within MRI environments.
Recent developments in nanotechnology are transforming the fields of biosensors, medical devices, diagnostics, high-throughput screening and drug delivery - and this is only the beginning! NanoBioConvergence is a non-profit organization that showcases applications of nanotech in the Life Sciences. Monthly programs present new technologies and discuss development, investment and IP issues vital to this emerging field. Presentations and content are available for download. Our programs should be of particular interest to investors and entrepreneurs in the corporate, government & academic sectors. For more information, please visit: http://www.nanobioconvergence.org.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat and optical catheter technologies. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.